34 results about "Blood vessel remodeling" patented technology

Described herein are vascular remodeling devices that include a proximal section, an intermediate section, and a distal section. During deployment, the proximal section can expand from a compressed delivery state to an expanded state and anchors the device in an afferent vessel of a bifurcation. The distal section expands from the compressed delivery state to an expanded state that may be substantially planar, approximately semi-spherical, umbrella shaped, or reverse umbrella shaped. The distal section is positioned in a bifurcation junction across the neck of an aneurysm or within an aneurysm. The intermediate section allows perfusion to efferent vessels. Before or after the device is in position, embolic material may be used to treat the aneurysm. The distal section can act as a scaffolding to prevent herniation of the embolic material. The device can be used for clot retrieval with integral distal embolic protection.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing pulmonary arterial hypertension and / or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

We report the use of telomerase-immortalized human microvascular endothelial cells in the formation of functional capillary blood vessels in vivo. Previously we showed the superior in vitro survival of human telomerase reverse transcriptase (hTERT)-transduced human endothelial cells. Here we show that retroviral-mediated transduction of hTERT in human dermal microvascular endothelial cells (HDMEC) results in cell lines that form microvascular structures when subcutaneously implanted in severe combined immunodeficiency (SCID) mice. The human origin of xenografted microvaculature was confirmed both by basement membrane immunoreactivity with anti-human type IV collagen staining and visualization of fluorescent vessels containing HDMEC that were co-transduced with hTERT and green fluorescent protein (eGFP). The lack of human vascular structures after implantation of HT1080 fibrosarcoma cells, 293 human embryonic kidney cells or human skin fibroblasts demonstrated the specificity of HDMEC at forming capillaries. Intravascular red fluorescent microspheres injected into the host circulation were found within green “telomerized” microvessels indicating functional murine-human vessel anastamoses. Whereas primary HDMEC-derived vessel density decreased steadily with time, telomerized HDMEC maintained durable vessels 6 weeks after xenografting. Modulation of implant vessel density by exposure to different angiogenic and angiostatic factors demonstrated the utility of this system for the study of human microvascular remodeling in vivo.

The invention discloses a cardiotonic capsule for treating chronic heart failure and belongs to the field of traditional Chinese medicines. A preparation method of the cardiotonic capsule comprises the following steps of mixing 3-5 parts by mass of milkvetch root, 3-5 parts by mass of red ginseng, 3-5 parts by mass of prepared monkshood, 2-10 parts by mass of semen lepidii, 3-5 parts by mass of radix ophiopogonis, 2-3 parts by mass of Chinese magnoliavine fruit, 2-3 parts by mass of polygonatum odoratum, 3-5 parts by mass of radix salviae miltiorrhizae, 2-3 parts by mass of ligusticum wallichii, 3-5 parts by mass of kudzuvine root powder, 3-5 parts by mass of radix notoginseng and 3-5 parts by mass of leech, crushing the mixture into fine powder, and filling the fine powder into capsules. The cardiotonic capsule for treating chronic heart failure does not produce any toxic and side effect, is not limited by contraindication, has good effects of treating chronic constrictive and diastolic heart failure, is especially suitable for diastolic heart failure, can improve heart failure symptoms, can correct heart failure pathological and physiological changes, can reverse atherosclerosis, and can improve ischemic myocardial injuries, cardiac muscle and blood vessel remodeling and long-term prognosis of heart failure patients.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The present invention is based on the finding that microRNA from the microRNA gene cluster located on the human chromosomal at locus 14q32 play an important role in vascular development and re-modelling. Modulators of any of the 14q32 microRNA may be exploited as a means to modulate vascular re-modelling processes and / or in the treatment and / or prevention of vascular disorders or disease.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The invention discloses a Chinese medicament kudzu-vine root for preventing and treating vascular restenosis, or a medicament composite comprising a kudzu-vine root which serves as a raw material, or the application of extractive which takes the kudzu-vine root as the raw material and serves as an active ingredient in the preparation of a medicament which is used for preventing and treating the vascular restenosis. The invention also discloses a method for preparing the medicament for preventing and treating the vascular restenosis. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis is novel medicament application besides the original published medicament effect of the kudzu-vine root. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis can obviously improve coronary heart diseases, apoplexy and sequel caused by atherosclerosis, and lumen restenosis caused by newly born endangium after angioplasty and artery scaffold treatment, regulate structural disorder caused by vascular remodeling, and effectively control thrombosis on an injured part and followed thrombus organization. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis has the advantages of positive clinical effects, obvious curative effect and quick response, and compared with a scaffold operation and a bypass operation, the Chinese medicament kudzu-vine root also has the advantages of higher safety, lower cost, and more stable and more reliable late result.

The invention provides application of a substance inhibiting angiopoietin-like protein 8. The application includes application of the substance inhibiting the angiopoietin-like protein 8 in preparation of products for preventing or treating diseases related to hypertension and / or vascular remodeling. The application of the substance inhibiting the angiopoietin-like protein 8 has the advantages that the substance inhibiting the angiopoietin-like protein 8 inhibits endoplasmic reticulum stress pathways of smooth muscle cells and suppresses proliferation and migration of the smooth muscle cells by inhibiting collagen deposition, and further can effectively reduce the blood pressure and the thickness of blood vessel walls, so that hypertension and vascular remodeling are prevented and treatedeffectively; the substance inhibiting the angiopoietin-like protein 8 can effectively improve the therapeutic effect on hypertension and vascular remodeling when being applied to the products for preventing or treating the diseases related to the hypertension and / or vascular remodeling, thereby having a good application prospect.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing pulmonary arterial hypertension and / or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.

The invention belongs to the technical field of medicines, and relates to applications of miR-9 in preparing medicines for treating acute coronary syndrome. MiR-9 can serve as a biomarker for patientssuffering from acute coronary syndrome and plays an important role in atherosclerotic plaque and blood vessel remodeling of the acute coronary syndrome, wherein the basic mechanism of the p38MAPK channel is related. MiR-9 can serve as a potential treatment target for the acute coronary syndrome.

The invention discloses a vascular wall elastic basement membrane and a preparation method thereof. The vascular wall elastic basement membrane is prepared from the following raw materials in parts by mass: 12-28 parts of collagens, 13-26 parts of hyaluronic acid, 12-30 parts of chitin, 10-22 parts of trehalose, 12-30 parts of fibroin, 12-20 parts of sericin, 8-22 parts of proline, 9-24 parts of lysine, 12-35 parts of cellulose, 1-7 parts of sodium carbonate and 25-60 parts of deionized water. Compared with the prior art, the vascular wall elastic basement membrane disclosed by the invention has the following advantages that (1) the prepared vascular wall elastic basement membrane is capable of effectively remodelling a vascular wall and increasing the success rate of a vascular remodelling operation; and (2) the prepared vascular wall elastic basement membrane is safe and non-toxic, free from side effects, convenient to use, and low in production cost.

The invention relates to miRNA, composition as well as an application of composition in disease diagnosis, in particular to miR-942-5p, miR-1262 as well as the application of composition of the miR-942-5p and the miR-1262 in diagnosis of myocardial infarction. The miRNA participates in different pathological processes of cardiovascular remodeling, including myocardial hypertrophy, fibrosis, myocardial function change, angiogenesis and the like, detection of dynamic change of miRNA can possibly provide clues for production and development of diseases, clinical early intervention is further guided, and the development of diseases is effectively controlled. The researched miR-942-5p and miR-1262 are closely related with myocardial infarction, can be used separately or jointly for clinical diagnosis and prevention detection of myocardial infarction and lay a foundation for research and development of clinically related diagnosis reagents.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The invention discloses an iron-based alloy degradable aorta stent for treating infant aortic constriction which comprises a stent body, the stent body is in a cylindrical hollow shape, annular rings are arranged at the two ends of the stent body, and the stent body is formed by connecting a plurality of rows of rhombus-shaped frames through V-shaped connecting rods. When the iron-based alloy degradable aorta stent is placed, aorta constriction can be relieved, acute dissection and aneurysm can be reduced, no metal is left after degradation, blood vessels are remodeled and grow, and if intervention is needed again, no matter a surgical operation or balloon dilatation or stent placement is affected. Due to the arrangement of the rhombus-shaped frame and the annular rings at the two ends and the middle of the stent, the stent has strong supporting force, the V-shaped connecting rod is easy to bend and can be used at the bending position of the blood vessel, the long axis shortening rate is reduced, and due to the frustum-shaped arrangement of the two ends of the stent, blood damage is reduced, and the thrombus risk is reduced.

The invention relates to the technical field of biological medicine, in particular to application of bone morphogenetic protein 6 in early diagnosis and treatment of preeclampsia. The invention provides application of BMP6 as a marker for early diagnosis / treatment of preeclampsia, application of BMP6 combined with PlGF and activin A in early diagnosis of preeclampsia, and application of BMP6 in preparation of drugs for prevention and treatment of preeclampsia. The invention finds that the BMP6, PlGF and activin A can improve the diagnosis effect of the existing diagnostic marker on preeclampsia in the preeclampsia early diagnosis; in addition, it is found that BMP6 can increase invasiveness and endothelial characteristic acquisition of human trophoblast cells, improve insufficient placental trophoblast invasion and poor vascular remodeling in the early stage of preeclampsia and then improve development of preeclampsia, and the BMP6 has the potential of preparing drugs for preventing and treating preeclampsia.

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.

The invention discloses applications of a transcription factor and an oncoprotein-ecotropic viral integration site 1 (EVI-1) inhibitor in vascular remodeling, wherein the EVI-1 inhibitor employs vascular smooth muscle specific marker gene (SMA, SM22, etc) and a specific transcription factor (SRF, Myocardin) as direct target points, thus improving expression of the smooth muscle specific gene, significantly inhibiting conversion from contractile type to secreting type of vascular medial smooth muscle cells, and further reducing abnormal regeneration of inner membrane after vascular injury. Theapplication is carried out from cell functional test into molecular mechanism researching at gene and protein levels, wherein an in-vivo animal pathological model test is converted into specimen analysis of clinical patients; all the results prove that the EVI-1 inhibitor is a key regulation factor for phenotypic transformation of smooth muscle cells; so there are reasons to believe that the EVI-1inhibitor is highly possible to be used as a novel anti-vascular anomaly remodeling medicine for treatment of cardiovascular and cerebrovascular diseases in future.